Transforming access to esophageal care
We are a leading gastrointestinal health company delivering minimally invasive diagnostics for everyone, everywhere.
Explore
Impact
Earlier matters
Esophageal cancer is one of the fastest-growing cancers. Barrett's Esophagus is the only known precursor to Esophageal Adenocarcinoma, yet fewer than 10% of patients have a prior diagnosis.
Only
1 in 5
people with esophageal
cancer survive their diagnosis
cancer survive their diagnosis
EndoSign® is a minimally-invasive capsule sponge device that enables safe and accessible cell collection with full esophageal sampling.
Learn more about our advanced molecular diagnostics:
Recent news
View All
Get in touch for more information about our early cancer test and data-driven diagnostics.
Get in touch
